James F. Oliviero III
2022
In 2022, James F. Oliviero III earned a total compensation of $2M as President, Chief Executive Officer and Director at Checkpoint Therapeutics, a 11% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $297,000 |
|---|---|
| Salary | $594,000 |
| Stock Awards | $1,151,150 |
| Total | $2,042,150 |
Oliviero received $1.2M in stock awards, accounting for 56% of the total pay in 2022.
Oliviero also received $297K in non-equity incentive plan and $594K in salary.
Rankings
In 2022, James F. Oliviero III's compensation ranked 1,725th out of 5,760 executives tracked by ExecPay. In other words, Oliviero earned more than 70.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,725 out of 5,760 | 70th |
Division Manufacturing | 904 out of 3,136 | 71st |
Major group Chemicals And Allied Products | 367 out of 1,422 | 74th |
Industry group Drugs | 335 out of 1,323 | 75th |
Industry Pharmaceutical Preparations | 240 out of 969 | 75th |
Source: SEC filing on May 1, 2023.
Oliviero's colleagues
We found one more compensation record of an executive who worked with James F. Oliviero III at Checkpoint Therapeutics in 2022.
2022
Garrett Gray
Checkpoint Therapeutics
Chief Financial Officer
News
Checkpoint Therapeutics CEO James Oliviero's 2023 pay slips 20% to $1.6M
April 2, 2024
Checkpoint Therapeutics CEO James Oliviero's 2022 pay slips 11% to $2M
May 1, 2023
Checkpoint Therapeutics CEO James Oliviero's 2021 pay stays at $2.3M
April 29, 2022
Checkpoint Therapeutics CEO James Oliviero's 2020 pay slips 1% to $2.3M
April 30, 2021
Checkpoint Therapeutics CEO James Oliviero's 2019 pay rises 8% to $2.3M
April 24, 2020
Checkpoint Therapeutics CEO James Oliviero's 2018 pay jumps 230% to $2.1M
April 30, 2019